Adaptimmune Therapeutics (ADAP)
NASDAQ: ADAP
· Real-Time Price · USD
0.28
0.02 (5.78%)
At close: May 16, 2025, 3:59 PM
0.27
-3.12%
After-hours: May 16, 2025, 07:34 PM EDT
Adaptimmune Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Development revenue Revenue | 176.8M | 60.28M | 27.15M | 6.15M |
| Development revenue Revenue Growth | +193.29% | +122.05% | +341.50% | n/a |
| Product revenue, net Revenue | 1.24M | n/a | n/a | n/a |
| Product revenue, net Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 23.28M | 21.22M | 21.28M | 16.36M | 19.73M | 14.15M | 16.16M | 20.07M | 20.4M | 15.22M | 16.82M | 16.89M | 16.8M | 14.78M | 15.17M | 14.99M | 13.82M | 13.24M | 13M | 10.29M | 9.26M | 10.73M | 10.74M | 10.15M | 11.77M | 10.82M | 10.29M | 11.29M | 11.2M | 8.82M | 8.11M | 7.71M | 6.46M | 6.34M | 5.42M | 6.81M | 5.86M | 6.12M | 4.88M | 5.49M | 2.36M |
| Selling, General, and Administrative Revenue Growth | +9.72% | -0.27% | +30.06% | -17.09% | +39.44% | -12.45% | -19.47% | -1.59% | +34.03% | -9.50% | -0.47% | +0.54% | +13.72% | -2.62% | +1.21% | +8.50% | +4.37% | +1.82% | +26.28% | +11.17% | -13.68% | -0.11% | +5.84% | -13.80% | +8.85% | +5.11% | -8.87% | +0.78% | +27.00% | +8.77% | +5.20% | +19.29% | +1.86% | +16.98% | -20.34% | +16.29% | -4.31% | +25.52% | -11.14% | +132.56% | n/a |
| Research and Development Revenue | 28.86M | 39.1M | 34.3M | 40.45M | 35.21M | 37.23M | 37.79M | 29.96M | 25.55M | 23.05M | 33.18M | 34.74M | 36.75M | 29.5M | 28.21M | 28.87M | 24.51M | 25.78M | 24.07M | 20.46M | 21.26M | 20.35M | 29.62M | 25.51M | 22.02M | 22.77M | 23.48M | 26.62M | 25.73M | 25.15M | 24.03M | 19.59M | 18.61M | 16.85M | 15.61M | 16.22M | 13.89M | 16.01M | 9.88M | 8.4M | 5.98M |
| Research and Development Revenue Growth | -26.20% | +13.98% | -15.19% | +14.89% | -5.42% | -1.49% | +26.11% | +17.29% | +10.83% | -30.53% | -4.48% | -5.47% | +24.56% | +4.59% | -2.28% | +17.80% | -4.93% | +7.11% | +17.63% | -3.78% | +4.47% | -31.28% | +16.10% | +15.86% | -3.29% | -3.04% | -11.79% | +3.47% | +2.32% | +4.64% | +22.68% | +5.24% | +10.49% | +7.92% | -3.75% | +16.78% | -13.28% | +62.00% | +17.62% | +40.63% | n/a |